Prosecution Insights
Last updated: October 02, 2026
Application No. 18/038,239

THIXOTROPIC DIUREA-DIURETHANE COMPOSITION

Non-Final OA §103
Filed
May 23, 2023
Priority
Dec 07, 2020 — FR FR.2012756 +1 more
Examiner
LEONARD, MICHAEL L
Art Unit
1763
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Arkema France
OA Round
3 (Non-Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
72%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
863 granted / 1355 resolved
-1.3% vs TC avg
Moderate +8% lift
Without
With
+8.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
55 currently pending
Career history
1400
Total Applications
across all art units

Statute-Specific Performance

§101
1.3%
-38.7% vs TC avg
§103
53.0%
+13.0% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
18.0%
-22.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1355 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 09/04/2026 has been entered. Claim Rejections - 35 USC § 103 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-4, 6, 8, 11, 18-22, 25-29, 31, and 40 are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent No. 10,882,944 to Haveman et al. in view of WO-2019/096611 to Kou et al. As to claims 1-4, 6, 8, 11, 18-22, 25-28, and 31, it should be noted that the compound of formula (II) is still optional. Haveman discloses a thixotropic composition comprising a compound represented by the following formula and an aprotic solvent wherein the compound comprises the reaction product of toluene diisocyanate and monohydroxyl compounds preferably polyethylene glycol monobutyl ether (hydrophilic) at a molar ratio of 1:1.05 to about 1:6 (5:1-18) to prepare a monoisocyanate reaction product that is reacted with xylylene diamine in the presence of solvent and surfactant (Examples, 11:1-36, Table 1). The monoisocyanate adduct comprises unreacted TDI that is removed by distillation. Haveman discloses wherein the composition contains small amounts (0.1 to about 1 wt%, 3:36-37), but preferably, no lithium salts from the viewpoint of improving the manufacturing process due to the corrosiveness associated with lithium (2:20-29). Haveman discloses a surfactant amount of 0.1 mols of surfactant calculated on the amine equivalent of diamine used (10:51-55). The molar ratio of monohydroxy compound to diisocyanate sits outside of the claimed range. However, in the same field of endeavor Kou teaches that providing total ratio of monohydroxyl compound to toluene diisocyanate in a range of from >1.0:1 to ≤ 1.5:1 leads to the formation of a urea-urethane polymer without necessitating a further distillation step of the diisocyanate and therefore improves economy of such production (see Kou, p. 3). Therefore, it would have been obvious to the person of ordinary skill in the art at the time of filing to have adjusted the ratio of monohydroxyl compound to toluene diisocyanate to within the above range to improve the economy of the process of making a urea-urethane compound (Kou, p. 3). The combination of references teaches a urea-urethane compound comprising an initial reaction product of a monohydroxy compound and a diisocyanate at a molar excess of hydroxy compounds (as taught in Kou) followed by the reaction with a diamine component. As taught by applicants, the presence of compound of formula (II) are a direct result of the molar ratio of monohydroxy compounds to diisocyanates. Because the ratio is taught within Kou and can be used within the preparation of the urea-urethanes of Haveman, the claimed compounds represented by formula (II) would be present including those within the claimed amounts. As to claims 12 and 15, Haveman and Kuo teach mixtures of diamines may be used, resulting in different R1 groups (Pg. 16, Kuo). As to claim 29, Haveman discloses a residual free isocyanate content of 0.1% (See Examples). As to claim 40, Haveman discloses a binder (paint, lacquer, or coating composition)comprising the urea urethane composition (10:58-67). Allowable Subject Matter Claims 32 and 36 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Response to Arguments Applicant’s arguments with respect to claim(s) 1-4, 6, 8, 11, 18-22, 25-29, 31, and 40 have been considered but are moot because the new ground of rejection does not rely on any reference applied in the prior rejection of record for any teaching or matter specifically challenged in the argument. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL L LEONARD whose telephone number is (571)270-7450. The examiner can normally be reached M - F 7:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached at 571-272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL L LEONARD/Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

May 23, 2023
Application Filed
Nov 24, 2025
Non-Final Rejection mailed — §103
May 26, 2026
Response Filed
Jun 10, 2026
Final Rejection mailed — §103
Sep 04, 2026
Request for Continued Examination
Sep 06, 2026
Response after Non-Final Action
Sep 24, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747355
RESIN COMPOSITION AND ARTICLE MADE THEREFROM
3y 0m to grant Granted Sep 29, 2026
Patent 12742042
POLYETHER DERIVATIVE AND PREPARATION METHOD THEREFOR
3y 6m to grant Granted Sep 22, 2026
Patent 12742037
Curable Photochromic Composition
2y 10m to grant Granted Sep 22, 2026
Patent 12735811
Polyurethane Elastic Fiber, Gather Member Containing Same, and Sanitary Material
3y 6m to grant Granted Sep 15, 2026
Patent 12735531
POLYPHENYLENE ETHER, PRODUCTION METHOD OF THE SAME, THERMOSETTING COMPOSITION, PREPREG, AND LAMINATE
3y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
72%
With Interview (+8.3%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1355 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month